Cepheid Stock Price, News & Analysis (NASDAQ:CPHD)

$52.95 0.00 (0.00 %)
(As of 01/19/2018 04:00 PM ET)
Previous Close$52.95
Today's Range$52.95 - $53.00
52-Week Range$25.09 - $53.91
Volume2.65 million shs
Average Volume1.25 million shs
Market CapitalizationN/A
P/E Ratio-77.87
Dividend YieldN/A
BetaN/A

About Cepheid (NASDAQ:CPHD)

Cepheid logoCepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to Deoxyribonucleic acid (DNA) amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.

Receive CPHD News and Ratings via Email

Sign-up to receive the latest news and ratings for CPHD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Diagnostic & Testing Equipment
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:CPHD
CUSIP15670R10
Phone+1-408-5414191

Debt

Debt-to-Equity Ratio0.76%
Current Ratio4.30%
Quick Ratio3.24%

Price-To-Earnings

Trailing P/E Ratio-77.8676470588235
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($0.68)
Net IncomeN/A
Net Margins-6.88%
Return on Equity-11.54%
Return on Assets-5.18%

Miscellaneous

Employees1,700
Outstanding Shares72,890,000

Cepheid (NASDAQ:CPHD) Frequently Asked Questions

What is Cepheid's stock symbol?

Cepheid trades on the NASDAQ under the ticker symbol "CPHD."

How were Cepheid's earnings last quarter?

Cepheid (NASDAQ:CPHD) posted its earnings results on Thursday, July, 28th. The scientific and technical instruments company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.19. The scientific and technical instruments company earned $146 million during the quarter, compared to analysts' expectations of $145.82 million. Cepheid had a negative net margin of 6.88% and a negative return on equity of 11.54%. The business's revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.06) EPS. View Cepheid's Earnings History.

Who are some of Cepheid's key competitors?

How do I buy Cepheid stock?

Shares of Cepheid can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cepheid's stock price today?

One share of Cepheid stock can currently be purchased for approximately $52.95.

How can I contact Cepheid?

Cepheid's mailing address is 904 E Caribbean Dr, SUNNYVALE, CA 94089-1189, United States. The scientific and technical instruments company can be reached via phone at +1-408-5414191.


MarketBeat Community Rating for Cepheid (CPHD)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  405 (Vote Outperform)
Underperform Votes:  401 (Vote Underperform)
Total Votes:  806
MarketBeat's community ratings are surveys of what our community members think about Cepheid and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cepheid (NASDAQ:CPHD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AHoldHold
Consensus Rating Score: N/AN/A2.002.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/A$45.40
Price Target Upside: N/AN/AN/A14.26% downside

Cepheid (NASDAQ:CPHD) Consensus Price Target History

Price Target History for Cepheid (NASDAQ:CPHD)

Cepheid (NASDAQ:CPHD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/22/2016Canaccord GenuityReiterated RatingHoldN/AView Rating Details
9/12/2016Robert W. BairdDowngradeOutperform -> Neutral$53.00N/AView Rating Details
9/8/2016CitigroupDowngradeBuy -> Neutral$44.00 -> $53.00N/AView Rating Details
9/7/2016BarclaysBoost Price TargetEqual Weight$36.00 -> $52.00N/AView Rating Details
9/7/2016BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
9/7/2016CowenDowngradeOutperform -> Market PerformN/AView Rating Details
9/6/2016Craig HallumDowngradeBuy -> HoldN/AView Rating Details
9/6/2016Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
9/6/2016Needham & Company LLCDowngradeBuy -> HoldN/AView Rating Details
8/17/2016Jefferies GroupBoost Price TargetHold$28.00 -> $34.00N/AView Rating Details
7/29/2016JPMorgan Chase & Co.Boost Price TargetNeutral$32.00 -> $35.00N/AView Rating Details
6/15/2016Morgan StanleyInitiated CoverageEqual Weight$30.00N/AView Rating Details
4/1/2016Atlantic SecuritiesUpgradeNeutral -> OverweightN/AView Rating Details
3/28/2016WedbushLower Price TargetOutperform$58.00 -> $55.00N/AView Rating Details
2/3/2016Stifel NicolausLower Price TargetBuy$42.00 -> $38.00N/AView Rating Details
2/3/2016Leerink SwannReiterated RatingMarket Perform$39.00 -> $33.00N/AView Rating Details
(Data available from 1/19/2016 forward)

Earnings

Cepheid (NASDAQ:CPHD) Earnings History and Estimates Chart

Earnings by Quarter for Cepheid (NASDAQ:CPHD)

Cepheid (NASDAQ CPHD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/28/2016Q216($0.14)$0.05$145.82 million$146.00 millionViewListenView Earnings Details
4/28/2016Q116$0.01$0.08$140.35 million$144.80 millionViewN/AView Earnings Details
2/2/2016Q415($0.20)($0.14)$146.95 million$147.00 millionViewN/AView Earnings Details
10/20/2015Q3($0.31)($0.13)$126.81 million$126.50 millionViewListenView Earnings Details
7/23/2015Q215($0.21)($0.06)$130.70 million$132.50 millionViewListenView Earnings Details
4/23/2015Q115($0.17)$0.06$125.50 million$132.60 millionViewN/AView Earnings Details
1/29/2015Q414($0.13)$0.11$125.34 million$131.50 millionViewN/AView Earnings Details
10/16/2014Q314($0.16)($0.10)$110.10 million$115.20 millionViewListenView Earnings Details
7/17/2014Q214($0.13)($0.10)$115.47 million$116.50 millionViewN/AView Earnings Details
4/17/2014Q114($0.19)($0.13)$104.90 million$106.90 millionViewN/AView Earnings Details
1/30/2014Q413($0.10)($0.07)$102.17 million$113.30 millionViewN/AView Earnings Details
10/17/2013Q3 2013($0.11)($0.02)ViewN/AView Earnings Details
7/18/2013Q2 2013$0.04$0.02$92.57 million$96.00 millionViewN/AView Earnings Details
4/18/2013Q1 2013$0.10$0.11$89.12 million$91.90 millionViewN/AView Earnings Details
1/24/2013Q4 2012$0.11$0.20$92.87 million$92.40 millionViewN/AView Earnings Details
10/18/2012($0.07)($0.32)ViewN/AView Earnings Details
7/19/2012$0.11$0.11ViewN/AView Earnings Details
4/19/2012($0.01)($0.08)ViewN/AView Earnings Details
1/26/2012($0.02)($0.03)ViewN/AView Earnings Details
10/20/2011$0.02$0.03ViewN/AView Earnings Details
7/21/2011($0.01)$0.03ViewN/AView Earnings Details
4/20/2011($0.01)$0.01ViewN/AView Earnings Details
1/27/2011($0.02)$0.02ViewN/AView Earnings Details
10/21/2010Q3 2010($0.06)($0.02)ViewN/AView Earnings Details
7/22/2010Q2 2010($0.10)($0.03)ViewN/AView Earnings Details
4/22/2010Q1 2010($0.10)($0.07)ViewN/AView Earnings Details
1/28/2010Q4 2009($0.12)($0.06)ViewN/AView Earnings Details
10/28/2009Q3 2009($0.12)($0.07)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.12)($0.12)ViewN/AView Earnings Details
4/23/2009Q1 2009($0.13)($0.13)ViewN/AView Earnings Details
2/5/2009Q4 2008($0.16)($0.10)ViewN/AView Earnings Details
10/28/2008Q3 2008($0.11)($0.11)ViewN/AView Earnings Details
7/24/2008Q2 2008($0.05)($0.13)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.07)($0.03)ViewN/AView Earnings Details
2/28/2008Q4 2007($0.08)($0.09)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Cepheid (NASDAQ:CPHD) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Cepheid (NASDAQ:CPHD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Cepheid (NASDAQ CPHD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.16%
Institutional Ownership Percentage: 95.75%
Insider Trades by Quarter for Cepheid (NASDAQ:CPHD)
Institutional Ownership by Quarter for Cepheid (NASDAQ:CPHD)

Cepheid (NASDAQ CPHD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/17/2016Scott A CampbellVPSell287$36.16$10,377.9210,376View SEC Filing  
8/4/2016Scott A CampbellVPSell746$36.71$27,385.6610,721View SEC Filing  
5/3/2016Scott A CampbellVPSell2,058$27.90$57,418.2013,761View SEC Filing  
5/2/2016Peter V FarrellEVPSell390$28.90$11,271.0019,837View SEC Filing  
4/28/2016Peter V FarrellEVPSell390$36.30$14,157.0020,462View SEC Filing  
4/25/2016John L BishopCEOSell110,000$35.50$3,905,000.00194,449View SEC Filing  
3/10/2016Peter V FarrellEVPSell393$33.01$12,972.9321,560View SEC Filing  
2/8/2016Warren C. Kocmond, Jr.COOSell292$28.53$8,330.7613,125View SEC Filing  
2/1/2016Warren C. Kocmond, Jr.COOSell351$28.44$9,982.4413,125View SEC Filing  
1/22/2016Warren C. Kocmond, Jr.COOSell157$33.16$5,206.1213,750View SEC Filing  
12/10/2015Peter V. FarrellEVPSell394$31.67$12,477.9821,975View SEC Filing  
11/20/2015Robert J EastonDirectorSell3,206$36.02$115,480.129,524View SEC Filing  
11/17/2015Robert J EastonDirectorSell2,724$34.84$94,904.169,524View SEC Filing  
11/12/2015Robert J EastonDirectorSell2,556$35.01$89,485.569,524View SEC Filing  
10/30/2015Peter V. FarrellEVPSell1,560$33.89$52,868.4023,238View SEC Filing  
8/27/2015Peter V. FarrellEVPSell1,577$48.67$76,752.5925,738View SEC Filing  
8/25/2015Cristina KepnerDirectorBuy10,000$47.78$477,800.00256,230View SEC Filing  
6/26/2015Warren C Kocmond JrCOOSell9,375$61.52$576,750.00View SEC Filing  
4/29/2015Thomas L GutshallDirectorSell1,800$56.62$101,916.00View SEC Filing  
4/21/2015Joseph H SmithEVPSell91,866$54.51$5,007,615.66View SEC Filing  
4/20/2015John L BishopCEOSell100,000$55.20$5,520,000.00View SEC Filing  
2/25/2015Hollings RentonDirectorSell9,375$57.76$541,500.00View SEC Filing  
2/13/2015Dean O MortonDirectorSell12,500$58.51$731,375.00View SEC Filing  
2/3/2015Thomas D BrownDirectorSell12,500$56.29$703,625.00View SEC Filing  
1/30/2015Andrew MillerCFOSell6,677$57.64$384,862.28View SEC Filing  
1/12/2015Andrew MillerCFOSell11,719$56.65$663,881.35View SEC Filing  
1/12/2015David H PersingEVPSell5,000$56.90$284,500.00View SEC Filing  
1/12/2015Warren C Kocmond JrCOOSell4,688$57.00$267,216.00View SEC Filing  
1/5/2015Andrew MillerCFOSell2,250$54.95$123,637.50View SEC Filing  
1/5/2015Kerry FlomEVPSell8,694$54.21$471,301.74View SEC Filing  
11/19/2014Dean O MortonDirectorSell11,849$52.96$627,523.04View SEC Filing  
11/7/2014Hollings RentonDirectorSell9,375$51.07$478,781.25View SEC Filing  
10/31/2014Andrew MillerCFOSell12,167$53.84$655,071.28View SEC Filing  
10/31/2014David H PersingEVPSell20,000$53.34$1,066,800.00View SEC Filing  
10/31/2014Dean O MortonDirectorSell7,500$52.64$394,800.00View SEC Filing  
10/29/2014Kerry FlomEVPSell7,077$51.36$363,474.72View SEC Filing  
10/29/2014Thomas L GutshallDirectorSell12,500$51.63$645,375.00View SEC Filing  
10/28/2014David H PersingEVPSell15,000$51.51$772,650.00View SEC Filing  
10/3/2014Kerry FlomEVPSell1,271$44.52$56,584.92View SEC Filing  
8/7/2014Warren C Kocmond JrEVPSell324$38.69$12,535.56View SEC Filing  
7/14/2014Kerry FlomEVPSell2,812$49.72$139,812.64View SEC Filing  
7/3/2014Kerry FlomEVPSell1,282$48.97$62,779.54View SEC Filing  
5/29/2014Kerry FlomEVPSell4,265$45.49$194,014.85View SEC Filing  
5/22/2014Warren C Kocmond JrEVPSell1,300$42.38$55,094.00View SEC Filing  
4/29/2014Kerry FlomEVPSell2,660$42.38$112,730.80989View SEC Filing  
4/25/2014John BishopCEOSell107,651$43.93$4,729,108.4341,105View SEC Filing  
4/22/2014John BishopCEOSell42,349$46.11$1,952,712.3939,850View SEC Filing  
4/22/2014Robert EastonDirectorSell12,500$45.59$569,875.0080,138View SEC Filing  
4/3/2014Kerry FlomEVPSell1,621$51.55$83,562.5520,000View SEC Filing  
4/1/2014Andrew MillerCFOSell4,688$52.78$247,432.644,584View SEC Filing  
3/13/2014Andrew MillerCFOSell17,265$55.55$959,070.754,584View SEC Filing  
1/31/2014Andrew MillerCFOSell63,375$53.10$3,365,212.504,584View SEC Filing  
1/31/2014John BishopCEOSell150,000$50.67$7,600,500.0039,176View SEC Filing  
1/31/2014Joseph SmithEVPSell50,000$51.15$2,557,500.0011,181View SEC Filing  
1/3/2014Kerry FlomEVPSell6,357$45.66$290,260.6220,000View SEC Filing  
1/2/2014Andrew MillerCFOSell2,437$45.92$111,907.042,683View SEC Filing  
12/23/2013Kerry FlomEVPSell10,000$46.51$465,100.0020,000View SEC Filing  
10/30/2013David H PersingVPSell5,000$41.35$206,750.00View SEC Filing  
10/29/2013Kerry FlomEVPSell2,660$40.50$107,730.00View SEC Filing  
10/24/2013Thomas L GutshallDirectorSell3,000$40.07$120,210.00View SEC Filing  
10/18/2013David H PersingVPSell20,000$40.59$811,800.00View SEC Filing  
9/24/2013Thomas GutshallDirectorSell3,000$38.97$116,910.0090,175View SEC Filing  
9/18/2013David PersingVPSell5,000$39.34$196,700.00177View SEC Filing  
9/16/2013David PersingVPSell5,000$38.95$194,750.00177View SEC Filing  
9/6/2013David H PersingVPSell20,000$37.99$759,800.00View SEC Filing  
8/30/2013David PersingVPSell5,129$36.62$187,823.98177View SEC Filing  
8/26/2013Thomas GutshallDirectorSell3,000$36.38$109,140.0090,175View SEC Filing  
8/21/2013Robert EastonDirectorSell7,500$35.01$262,575.0079,124View SEC Filing  
7/24/2013Thomas L GutshallDirectorSell3,000$34.18$102,540.00View SEC Filing  
6/24/2013Thomas L GutshallDirectorSell3,000$32.91$98,730.00View SEC Filing  
5/28/2013Andrew MillerCFOSell22,468$38.51$865,242.68View SEC Filing  
5/24/2013Thomas L GutshallDirectorSell3,000$37.90$113,700.00View SEC Filing  
5/13/2013Kerry FlomEVPSell6,832$39.76$271,640.32View SEC Filing  
3/25/2013Thomas L GutshallDirectorSell3,000$38.28$114,840.00View SEC Filing  
2/4/2013Joseph H SmithEVPSell38,400$36.20$1,390,080.00View SEC Filing  
12/24/2012Thomas L GutshallDirectorSell3,000$33.06$99,180.00View SEC Filing  
11/26/2012Thomas L GutshallDirectorSell7,778$31.94$248,429.32View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cepheid (NASDAQ CPHD) News Headlines

Source:
DateHeadline
Cepheid expands respiratory disease portfolio with Xpert Xpress Strep ACepheid expands respiratory disease portfolio with Xpert Xpress Strep A
seekingalpha.com - October 5 at 11:03 AM
Head to Head Contrast: Cepheid (CPHD) vs. Varex Imaging (VREX)Head to Head Contrast: Cepheid (CPHD) vs. Varex Imaging (VREX)
www.americanbankingnews.com - September 9 at 4:06 AM
Contrasting Cepheid (CPHD) and HTG Molecular Diagnostics (HTGM)Contrasting Cepheid (CPHD) and HTG Molecular Diagnostics (HTGM)
www.americanbankingnews.com - August 5 at 7:06 AM
Financial Review: Sequenom (SQNM) & Cepheid (CPHD)Financial Review: Sequenom (SQNM) & Cepheid (CPHD)
www.americanbankingnews.com - August 1 at 8:30 PM
Contrasting Cepheid (NASDAQ:CPHD) and Myriad Genetics (MYGN)Contrasting Cepheid (NASDAQ:CPHD) and Myriad Genetics (MYGN)
www.americanbankingnews.com - July 30 at 7:27 AM
Comparing Myriad Genetics (MYGN) & Cepheid (NASDAQ:CPHD)Comparing Myriad Genetics (MYGN) & Cepheid (NASDAQ:CPHD)
www.americanbankingnews.com - July 29 at 10:11 AM
Reviewing Cepheid (CPHD) & Vascular Solutions (VASC)Reviewing Cepheid (CPHD) & Vascular Solutions (VASC)
www.americanbankingnews.com - July 28 at 7:14 AM
Head-To-Head Comparison: Myriad Genetics (MYGN) vs. Cepheid (CPHD)Head-To-Head Comparison: Myriad Genetics (MYGN) vs. Cepheid (CPHD)
www.americanbankingnews.com - July 22 at 7:36 AM
Head to Head Survey: Cepheid (NASDAQ:CPHD) versus Myriad Genetics (MYGN)Head to Head Survey: Cepheid (NASDAQ:CPHD) versus Myriad Genetics (MYGN)
www.americanbankingnews.com - July 21 at 8:04 AM
Analyzing Cepheid (CPHD) and Alphatec Holdings (ATEC)Analyzing Cepheid (CPHD) and Alphatec Holdings (ATEC)
www.americanbankingnews.com - July 20 at 9:42 AM
Comparing Myriad Genetics (MYGN) & Cepheid (CPHD)Comparing Myriad Genetics (MYGN) & Cepheid (CPHD)
www.americanbankingnews.com - July 14 at 8:36 AM
Head-To-Head Comparison: Alphatec Holdings (ATEC) vs. Cepheid (NASDAQ:CPHD)Head-To-Head Comparison: Alphatec Holdings (ATEC) vs. Cepheid (NASDAQ:CPHD)
www.americanbankingnews.com - July 12 at 8:16 AM
These drug and medical device companies made the most payments to L.A. hospitalsThese drug and medical device companies made the most payments to L.A. hospitals
www.bizjournals.com - March 3 at 9:29 PM
Integrated Investment Consultants, LLC Buys Vanguard FTSE Emerging Markets, Mylan NV, Omega ...Integrated Investment Consultants, LLC Buys Vanguard FTSE Emerging Markets, Mylan NV, Omega ...
www.nasdaq.com - January 19 at 10:48 PM
Danaher initiates 2017 outlookDanaher initiates 2017 outlook
seekingalpha.com - December 15 at 4:53 PM
CEPHEID Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate orCEPHEID Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or
biz.yahoo.com - November 7 at 11:02 PM
Danaher (DHR) Announces Completion of Cepheid (CPHD) Acquisition - StreetInsider.comDanaher (DHR) Announces Completion of Cepheid (CPHD) Acquisition - StreetInsider.com
www.streetinsider.com - November 7 at 7:55 AM
CEPHEID Files SEC form 10-Q, Quarterly ReportCEPHEID Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - November 3 at 9:56 PM
CEPHEID Files SEC form 8-K, Change in Directors or Principal OfficersCEPHEID Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - October 28 at 9:11 PM
IWO, MSCC, AZPN, CPHD: Large Outflows Detected at ETFIWO, MSCC, AZPN, CPHD: Large Outflows Detected at ETF
www.nasdaq.com - October 25 at 9:37 PM
Cepheid Says Receives Regulatory Clearances In Proposed Acquisition By DanaherCepheid Says Receives Regulatory Clearances In Proposed Acquisition By Danaher
www.nasdaq.com - October 24 at 4:16 PM
Cepheid (CPHD) Announces Final Regulatory Hurdles Cleared to Close Danaher (DHR) MergerCepheid (CPHD) Announces Final Regulatory Hurdles Cleared to Close Danaher (DHR) Merger
www.streetinsider.com - October 24 at 4:16 PM
Cepheid (CPHD) Announces Final Regulatory Hurdles Cleared to Close Danaher (DHR) Merger - StreetInsider.comCepheid (CPHD) Announces Final Regulatory Hurdles Cleared to Close Danaher (DHR) Merger - StreetInsider.com
www.streetinsider.com - October 24 at 9:34 AM
CEPHEID Files SEC form 8-K, Other Events, Financial Statements and ExhibitsCEPHEID Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - October 24 at 9:33 AM
iShares Russell 2000 Growth ETF Experiences Big OutflowiShares Russell 2000 Growth ETF Experiences Big Outflow
www.nasdaq.com - October 14 at 4:15 PM

SEC Filings

Cepheid (NASDAQ:CPHD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cepheid (NASDAQ:CPHD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cepheid (NASDAQ CPHD) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.